Genvor Appoints Seasoned CFO with IPO Experience Amidst Going Concern Warning

summarizeSummary

Genvor Inc. has appointed Donald Kalkofen, a seasoned CFO with extensive IPO and capital markets experience, to lead its financial strategy and support its uplisting goals, following a recent 'going concern' warning.

check_boxKey Events

• New Chief Financial Officer Appointed

  Donald Kalkofen, a CFO with over 20 years of experience in biotechnology and financial services, including guiding companies through IPOs and capital markets transactions, was appointed effective May 18, 2026.

• Amended Compensation Agreement

  The company entered into an Amended and Restated Acting CFO Services Agreement on May 21, 2026, superseding a prior agreement from May 18, 2026. The agreement outlines cash compensation and equity incentives.

• Significant Compensation Package

  Mr. Kalkofen will receive $6,250 per month in current cash compensation and $7,750 per month in deferred cash compensation. The aggregate deferred compensation is due by December 31, 2026, with potential deferral up to 24 months if payment jeopardizes the company's going concern status. Monthly cash compensation increases to $14,000 from January 1, 2027.

• Equity Compensation with Contingencies

  Mr. Kalkofen is to be granted 575,000 ten-year stock options. The grant is contingent on Board approval of an equity compensation plan within 30 days and subsequent shareholder approval by the next meeting. Options are not exercisable until an S-8 registration statement is effective.

auto_awesomeAnalysis

Genvor Inc., recently flagged with a 'going concern' warning and critical internal control failures, has appointed Donald Kalkofen as its Chief Financial Officer. Mr. Kalkofen brings over 20 years of experience, including guiding companies through IPOs and complex capital markets transactions, which is crucial for Genvor's stated goal of uplisting to a national exchange. This appointment is a critical step in addressing the company's severe financial instability, though the compensation package, including significant deferred cash and stock options, adds to the company's liabilities and potential future dilution.